share_log

歌禮製藥-B:翌日披露報表

ASCLETIS-B: Next Day Disclosure Return

香港交易所 ·  Feb 16 05:44
Summary by Moomoo AI
歌禮製藥有限公司於2024年2月16日提交了翌日披露報表,披露了自2023年12月19日至2024年2月16日期間的股份購回活動。該公司在此期間共購回股份數目達68,245,000股,佔已發行股份的6.2775%。最後一次購回發生在2024年2月16日,當日購回145,000股,每股價格介乎HKD 1.73至HKD 1.8,總付出金額為HKD 259,250。根據香港聯合交易所有限公司證券上市規則,公司已完成所有必要的披露和法律程序,並確認所有購回活動均獲得董事會正式授權批准。
歌禮製藥有限公司於2024年2月16日提交了翌日披露報表,披露了自2023年12月19日至2024年2月16日期間的股份購回活動。該公司在此期間共購回股份數目達68,245,000股,佔已發行股份的6.2775%。最後一次購回發生在2024年2月16日,當日購回145,000股,每股價格介乎HKD 1.73至HKD 1.8,總付出金額為HKD 259,250。根據香港聯合交易所有限公司證券上市規則,公司已完成所有必要的披露和法律程序,並確認所有購回活動均獲得董事會正式授權批准。
Song Pharmaceutical Co., Ltd. filed a Next Day Disclosure Report on February 16, 2024, disclosing its share repurchase activities for the period from December 19, 2023 to February 16, 2024. During this period, the company repurchased 68,245,000 shares, representing 6.2775% of the issued shares. The last repurchase took place on 16 February 2024 and repurchased 145,000 shares at a price of HKD 1.73 to HKD 1.8 for a total payout of HKD 259,250. Pursuant to the Listing Rules of the Stock Exchange of Hong Kong Limited, the Company has completed all necessary disclosure and legal procedures and confirmed that all repurchase activities are formally authorized by the Board of Directors.
Song Pharmaceutical Co., Ltd. filed a Next Day Disclosure Report on February 16, 2024, disclosing its share repurchase activities for the period from December 19, 2023 to February 16, 2024. During this period, the company repurchased 68,245,000 shares, representing 6.2775% of the issued shares. The last repurchase took place on 16 February 2024 and repurchased 145,000 shares at a price of HKD 1.73 to HKD 1.8 for a total payout of HKD 259,250. Pursuant to the Listing Rules of the Stock Exchange of Hong Kong Limited, the Company has completed all necessary disclosure and legal procedures and confirmed that all repurchase activities are formally authorized by the Board of Directors.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more